Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Recombinant interleukin-20 (rIL-20) is a synthetic form of the IL-20 cytokine, a member of the IL-10 family. It acts as an agonist that signals through two distinct heterodimeric receptor complexes: the Type I receptor (composed of IL-20RA and IL-20RB) and the Type II receptor (composed of IL-22RA1 and IL-20RB). IL-20 is primarily involved in regulating epithelial cell functions, including proliferation, differentiation, and tissue repair, particularly in the skin and respiratory tract. While it plays a physiological role in wound healing, its dysregulation is implicated in inflammatory pathologies such as psoriasis and chronic obstructive pulmonary disease (COPD). In research settings, recombinant IL-20 is used to study its effects on epithelial barrier integrity and its potential as a biomarker or therapeutic target in chronic inflammatory diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on recombinant interleukin-20.